A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global pivotal trial will be in first-line triple-negative breast cancer.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
The group will need to wait for more data with its neoantigen immunotherapy Granite, but cash is running short.
A roundup of the first quarter's key oncology drug approvals and rejections.
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.